



Contact: Angela Strand  
(415) 902-3762

FOR IMMEDIATE RELEASE

## **Proteus Biomedical Announces Appointment of Independent Directors**

*Accelerates Expansion of Pharmaceutical, Hospital Businesses*

**Redwood City, Calif.**, January 7<sup>th</sup>, -- (Business Wire) -- Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Ms. Ginger Graham and Ms. Kathy Murray have been appointed to serve on its divisional Boards of Directors. Graham and Murray join a distinguished group of independent directors at Proteus that includes Frank Fischer, Alan Levy and Ben Pless.

“Ginger Graham and Kathy Murray bring extensive strategy, development and operational experience to Proteus at an important point in the company’s evolution,” said Andrew Thompson, Proteus’ chief executive officer. “As we expand the applications of our technologies beyond therapeutic devices to pharmaceutical and hospital products, it is imperative that we leverage the strategic guidance of recognized leaders with proven track records in their fields.”

Graham will serve on Proteus’ pharmaceutical systems division board and focus on the development and commercialization strategies for its intelligent pharmaceutical products. The company has developed a clinical-stage technology platform to personalize, monitor and manage drug ingestion and physiologic drug response based on novel intelligent medicine formulations of existing pharmaceutical products. The first of these products, focused on heart failure and psychiatric disorders, enter clinical study in 2008.

Graham commented, “Proteus has an extraordinary combination of unique technologies, diverse management talent and multiple compelling clinical applications. The company’s vision for personalizing proven pharmaceutical therapies represents a significant opportunity.”

Graham was most recently chief executive officer of Amylin Pharmaceuticals, a publicly traded biopharmaceutical company. During her tenure, she led the company through the development and launch of its flagship product, Byetta, a revolutionary new product for people with diabetes. She previously held executive leadership positions at Guidant Corporation and Eli Lilly and Company.

Murray will serve on Proteus' hospital systems division board and focus on the development of its intelligent medication delivery and patient care management products. The company is developing a technology platform that integrates patient physiologic response with multiple treatment variables to personalize and improve the control of hospital-based therapies. The first of these products is in pre-clinical development.

“Proteus is addressing significant unmet needs relating to the safe, reliable delivery of medical care within the hospital setting. These products offer the potential to improve outcomes and reduce medical errors by delivering actionable information to clinicians to ensure the right therapy is delivered at the right time,” Murray said.

Kathy Murray is a director of Covance, a publicly traded drug development services company. During the prior twenty years she served in leadership positions with Northwestern Memorial Corporation in Chicago, including both chief operating officer of the Hospital and Corporation and chief executive officer of the Foundation. Murray also served as chair of the Illinois Hospital Association and chair of the Metropolitan Hospitals Governing Council of the American Hospital Association.

### **About Proteus Biomedical**

Proteus Biomedical is pioneering intelligent medicine, an emerging field of advanced therapeutics that integrates in-body computer, sensor and communications technologies into existing medical device, pharmaceutical and hospital products. Proteus' proprietary computing and sensing technologies enable proven therapies to be personalized, offering broad potential benefits across a range of care settings and therapeutic areas, including cardiovascular, psychiatric, metabolic and neurologic disorders. The company's first product, a novel pacing and sensor-enabled device for Cardiac Resynchronization Therapy, is in development in collaboration with a world leader in cardiovascular implantable devices.

More information about Proteus Biomedical can be found at [www.proteusbiomed.com](http://www.proteusbiomed.com).

# # #